Patent intelligence · US
US 2024398790
TREATING SPONDYLOARTHRITIC CONDITIONS WITH UPADACITINIB
TREATING SPONDYLOARTHRITIC CONDITIONS WITH UPADACITINIB
Patent details — US 2024398790
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 5, 2024
- Expiration
- Nov 30, 2044
- Applicant
- ABBVIE INC [US]
- CPC classes
- A61K 9/ 00 A I, A61K 31/ 4985 A I, A61K/314985, A61K/31519
Quick answer
US 2024398790 (TREATING SPONDYLOARTHRITIC CONDITIONS WITH UPADACITINIB) is held by ABBVIE INC [US]. Status: granted. Granted Dec 5, 2024. Expires Nov 30, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ABBVIE INC [US]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 00 A I, A61K 31/ 4985 A I, A61K/314985, A61K/31519, A61K/90053, A61K/92077
More from ABBVIE INC [US]
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 2024398790?
US 2024398790 (TREATING SPONDYLOARTHRITIC CONDITIONS WITH UPADACITINIB) is held by ABBVIE INC [US]. Status: granted. Granted Dec 5, 2024. Expires Nov 30, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 2024398790?
ABBVIE INC [US] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does US 2024398790 expire?
Our index shows an expiration date of Nov 30, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.